The patentability of biotech inventions should meet substantive requirements such as novelty, inventive step and industrial applicability, but EPO developments suggest that formalities are increasingly important.
The rules for filing European divisional applications have been drastically limited for applicants for two years.
Since April 1, 2010, the rules for filing a European divisional patent application have been restricted—rules 36(1)(a) and 36(1) (b). Under rule 36(1)(a), an applicant has 24 months to file a European divisional calculated from the first European office action of the earliest application, the so-called ‘voluntary divisional’.
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email James Lynn on email@example.com.
invention, biotechnology, EPO, industrial applicability